{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:35:46Z","timestamp":1792460146835,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":706,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1038\/mt.2014.138","type":"journal-article","created":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T11:17:46Z","timestamp":1406114266000},"page":"2004-2012","source":"Crossref","is-referenced-by-count":91,"title":["A Chaperone Enhances Blood \u03b1-Glucosidase Activity in Pompe Disease Patients Treated With Enzyme Replacement Therapy"],"prefix":"10.1016","volume":"22","author":[{"given":"Giancarlo","family":"Parenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Fecarotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"la Marca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Ascione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alice","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Ovidia","family":"Morandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Ravaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pichiecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Ombrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Sacchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Barbara","family":"Pasanisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"De Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Danesino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Della Casa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Mollica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Agovino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Nusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Generoso","family":"Andria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2014.138_bib1","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1038\/mt.2014.138_bib2","first-page":"S42","article-title":"Autophagy in skeletal muscle: implications for Pompe disease","volume":"47(suppl. 1)","author":"Shea","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1038\/mt.2014.138_bib3","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1073\/pnas.0902534106","article-title":"Neural deficits contribute to respiratory insufficiency in Pompe disease","volume":"106","author":"DeRuisseau","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2014.138_bib4","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/mt.2013.96","article-title":"Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease","volume":"21","author":"Falk","year":"2013","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.138_bib5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","article-title":"Recombinant human alpha-glucosidase from rabbit milk in Pompe patients","volume":"356","author":"Van den Hout","year":"2000","journal-title":"Lancet"},{"key":"10.1038\/mt.2014.138_bib6","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"key":"10.1038\/mt.2014.138_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1038\/mt.2014.138_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2010","journal-title":"J Neurol"},{"key":"10.1038\/mt.2014.138_bib9","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2014.138_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajmg.c.31321","article-title":"Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations","volume":"160C","author":"Case","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1038\/mt.2014.138_bib11","doi-asserted-by":"crossref","first-page":"e1116","DOI":"10.1542\/peds.2008-3667","article-title":"Pompe disease in infants: improving the prognosis by newborn screening and early treatment","volume":"124","author":"Chien","year":"2009","journal-title":"Pediatrics"},{"key":"10.1038\/mt.2014.138_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2014.138_bib13","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.mt.6300074","article-title":"Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease","volume":"15","author":"Parenti","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.138_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2006.09.010","article-title":"Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II","volume":"90","author":"Okumiya","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2014.138_bib15","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/mt.2009.53","article-title":"The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts","volume":"17","author":"Porto","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.138_bib16","doi-asserted-by":"crossref","first-page":"e40776","DOI":"10.1371\/journal.pone.0040776","article-title":"The pharmacological chaperone AT2220 increases recombinant human acid a-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease","volume":"7","author":"Khanna","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1038\/mt.2014.138_bib17","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1038\/mt.2014.138_bib18","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(07)70194-1","article-title":"Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study","volume":"6","author":"Patterson","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1038\/mt.2014.138_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.nmd.2003.08.003","article-title":"Muscle MRI in adult-onset acid maltase deficiency","volume":"14","author":"Pichiecchio","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1038\/mt.2014.138_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1203\/00006450-199602000-00021","article-title":"Turnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissues","volume":"39","author":"Xu","year":"1996","journal-title":"Pediatr Res"},{"key":"10.1038\/mt.2014.138_bib21","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/mt.2012.152","article-title":"Pharmacological enhancement of a-glucosidase by the allosteric chaperone N-acetylcysteine","volume":"20","author":"Porto","year":"2012","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.138_bib22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2011.271","article-title":"Co-administration with the pharmacological chaperone AT1001 increases recombinant human a-galactosidase A tissue uptake and improves substrate reduction in Fabry mice","volume":"20","author":"Benjamin","year":"2012","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.138_bib23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10545-011-9424-3","article-title":"Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease","volume":"35","author":"Porto","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mt.2014.138_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nchembio850","article-title":"Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease","volume":"3","author":"Lieberman","year":"2007","journal-title":"Nat Chem Biol"},{"key":"10.1038\/mt.2014.138_bib25","unstructured":"ClinicalTrial.gov Trial identifier NCT01380743. http:\/\/clinicaltrials.gov\/show\/NCT01380743"},{"key":"10.1038\/mt.2014.138_bib26","unstructured":"ClinicalTrial.gov Trial identifier NCT01196871 http:\/\/clinicaltrials.gov\/show\/NCT01196871"},{"key":"10.1038\/mt.2014.138_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1755-8417-1-6","article-title":"Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts","volume":"1","author":"Cardone","year":"2008","journal-title":"Pathogenetics"},{"key":"10.1038\/mt.2014.138_bib28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1750-1172-8-160","article-title":"The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?","volume":"8","author":"Lachmann","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1038\/mt.2014.138_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16390","article-title":"The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders","volume":"16","author":"Wyatt","year":"2012","journal-title":"Health Technol Assess"},{"key":"10.1038\/mt.2014.138_bib30","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","article-title":"Glycosylation-independent lysosomal targeting of acid a-glucosidase enhances muscle glycogen clearance in pompe mice","volume":"288","author":"Maga","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2014.138_bib31","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.138_bib32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymgme.2011.11.005","article-title":"\u00df2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease","volume":"105","author":"Koeberl","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2014.138_bib33","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1096\/fj.13-241893","article-title":"Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease","volume":"28","author":"Koeberl","year":"2014","journal-title":"FASEB J"},{"key":"10.1038\/mt.2014.138_bib34","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1021\/ac900504s","article-title":"New strategy for the screening of lysosomal storage disorders: the use of the online trapping-and-cleanup liquid chromatography\/mass spectrometry","volume":"81","author":"la Marca","year":"2009","journal-title":"Anal Chem"},{"key":"10.1038\/mt.2014.138_bib35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/abio.2000.4838","article-title":"Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease","volume":"287","author":"An","year":"2000","journal-title":"Anal Biochem"},{"key":"10.1038\/mt.2014.138_bib36","unstructured":"Gross Motor Function Measure (GMFM), Version 1.0 2002 Mac Keith Press London"},{"key":"10.1038\/mt.2014.138_bib37","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/mus.880040304","article-title":"Clinical trial in Duchenne dystrophy. I. The design of the protocol","volume":"4","author":"Brooke","year":"1981","journal-title":"Muscle Nerve"},{"key":"10.1038\/mt.2014.138_bib38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1038\/mt.2014.138_bib39","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1249\/00005768-198205000-00012","article-title":"Psychophysical bases of perceived exertion","volume":"14","author":"Borg","year":"1982","journal-title":"Med Sci Sports Exerc"},{"key":"10.1038\/mt.2014.138_bib40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1090-3798(02)90617-3","article-title":"A short protocol for muscle MRI in children with muscular dystrophies","volume":"6","author":"Mercuri","year":"2002","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1038\/mt.2014.138_bib41","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J Biol Chem"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616302453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616302453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T11:53:25Z","timestamp":1538394805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616302453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S1525001616302453"],"URL":"https:\/\/doi.org\/10.1038\/mt.2014.138","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}